Cd1d regulation and its effect on NKT cell activation
Cd1d regulation and its effect on NKT cell activation
批准号:
7288349
负责人:
SAMUEL M BEHAR
金额:
$47.72万
依托单位国家:
美国
项目类别:
财政年份:
2006
资助国家:
美国
项目状态:
已结题
起止时间:
2006-09-18 至 2011-05-31
关键词:
AffectAnimalsAntigen PresentationAntigen ReceptorsAntigen-Presenting CellsAntigensAutoantigensAutoimmune DiseasesBacteriaBiologyCell surfaceCellsClassCommunicable DiseasesConditionDataDetectionGrantHistocompatibility TestingHost DefenseHost resistanceHumanHybridomasImmune responseImmune systemImmunityInfectionInflammationInflammatoryInflammatory ResponseLigandsLipidsMediatingModelingMolecularMusNatural Killer CellsNumbersParasitesPharmaceutical PreparationsPhysiologicalPlayProcessPropertyProteinsReceptor SignalingRegulationResearch PersonnelRoleSignal TransductionSignal Transduction PathwayT-LymphocyteTNF geneThinkingTissuesToll-like receptorsTumor ImmunityTumor Necrosis Factor ReceptorUp-RegulationVaccinesVirusantimicrobialautoreactivitycytokinefungusin vivoinsightinterestmacrophagemicrobialmicroorganism antigennovelpathogenpreventprogramsreceptorresponse
中文摘要
描述(申请人提供):NKT细胞是一种独特的T细胞,具有与NK细胞相同的某些特性,并识别CD1d提呈的脂类抗原。CD1d和NKT细胞是人类和小鼠之间进化保守的细胞,小鼠模型对CD1d和CD1d限制性T细胞的生物学提供了相当大的洞察力。根据模型的不同,NKT细胞要么促进,要么抑制与自身免疫性疾病相关的组织炎症。CD1d限制的NKT细胞在宿主对多种病原体的免疫中也做出了重要贡献,包括寄生虫、真菌、病毒和细菌。NKT细胞识别什么抗原尚不清楚。越来越多的研究表明,CD1d呈现的是自身脂类抗原。如果内源性配体激活NKT细胞,则必须调节CD1d的抗原提呈,以防止NKT细胞的不适当激活。这项资助的重点是确定APC上CD1d的表达是如何调节的,以及它的调节是否影响CDID限制的免疫反应。虽然对CD1d的调控知之甚少,但我们已经观察到细胞因子和微生物产物协同诱导CD1d的表达。正如I类和II类MHC分子上调促进MHC限制性免疫反应一样,CD1d上调可能促进NKT细胞激活。我们假设在感染后,通过Toll样受体(TLR)和IFNγ受体的信号导致APC上CD1d的细胞表面表达增加。这将反过来促进CD1d限制的NKT细胞的激活,当刺激时,NKT细胞具有抗菌和免疫调节特性。这项资助将决定细胞表面CD1d水平是否调节原代NKT细胞的激活。我们将继续确定组织炎症是否在体内诱导CD1d,以及CD1d水平是否影响体内NKT细胞的激活。最后,我们将确定细胞因子和微生物产物如何产生细胞内信号来导致CD1d上调,以及CD1d表达是如何在分子水平上调节的。了解CD1是如何调控的,以及感染后NKT细胞是如何激活的,这将有助于阐明NKT细胞在对人类病原体的免疫中的作用,并有助于深入了解它们在其他免疫反应中的生理作用。
英文摘要
DESCRIPTION (provided by applicant): NKT cells are unique T cells that share some properties with NK cells and recognize lipid antigens presented by CD1d. CD1d and NKT cells are evolutionary conserved between humans and mice, and the murine model has provided considerable insight into the biology of CD1d and CD1d- restricted T cells. Depending on the model, NKT cells either contribute to, or suppress, tissue inflammation associated with autoimmune disease. CD1d-restricted NKT cells also make a critical contribution to host immunity against many diverse pathogens, including parasites, fungi, viruses and bacteria. What antigens NKT cells recognize is unknown. Increasingly, it appears that CD1d presents self-lipid antigens. If endogenous ligands activate NKT cells, then antigen presentation by CD1d must be regulated to prevent inappropriate activation of NKT cells. The focus of this grant is to determine how CD1d expression on APC is regulated and whether its modulation influences CDId-restricted immune responses. Although little is known about CD1d regulation, we have observed that cytokines and microbial products synergize to induce CD1d expression. Just as upregulation of class I and II MHC molecules promote MHC-restricted immune responses, upregulation of CD1d may promote NKT cell activation. We hypothesize that following infection, signaling through Toll-like Receptors (TLR) and the IFNgamma-receptor leads to increased cell surface expression of CD1d on APC. This will in turn promote activation of CD1d-restricted NKT cells, which when stimulated, have antimicrobial and immunoregulatory properties. This grant will determine whether cell surface CD1d levels modulate the activation of primary NKT cells. We will go on to determine whether tissue inflammation induces CD1d in vivo, and whether CD1d levels affect the activation of NKT cells in vivo. Finally we will determine how cytokines and microbial products generate an intracellular signal to cause CD1d upregulation, and how the CD1d expression is regulated at the molecular level. Understanding how CD1 is regulated and how NKT cells become activated following infection will clarify the role of NKT cells in immunity to human pathogens, as well as provide insight into their physiological role in other immune responses.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
The role of CD38 in immunity to tuberculosis
-
批准号:10727585
-
项目类别:
-
资助金额:$25.13万
-
财政年份:2023
-
负责人:SAMUEL M BEHAR
-
依托单位:
Hypoxia, tuberculosis, and T cell dysfunction
-
批准号:10735553
-
项目类别:
-
资助金额:$72.97万
-
财政年份:2023
-
负责人:SAMUEL M BEHAR
-
依托单位:
Granulysin and the antimicrobial activity of CD8T cells - development of a better model
-
批准号:10192536
-
项目类别:
-
资助金额:$20.94万
-
财政年份:2021
-
负责人:SAMUEL M BEHAR
-
依托单位:
Granulysin and the antimicrobial activity of CD8T cells - development of a better model
-
批准号:10356169
-
项目类别:
-
资助金额:$25.13万
-
财政年份:2021
-
负责人:SAMUEL M BEHAR
-
依托单位:
Overcoming Genetic Variation in Vaccination
-
批准号:10219089
-
项目类别:
-
资助金额:$42.52万
-
财政年份:2017
-
负责人:SAMUEL M BEHAR
-
依托单位:
Tuberculosis and T cell Recognition
-
批准号:9081934
-
项目类别:
-
资助金额:$73.55万
-
财政年份:2016
-
负责人:SAMUEL M BEHAR
-
依托单位:
Tuberculosis and T cell Recognition
-
批准号:9221970
-
项目类别:
-
资助金额:$69.83万
-
财政年份:2016
-
负责人:SAMUEL M BEHAR
-
依托单位:
Regulation of CD8+ T cell immunity to tuberculosis (pending title)
-
批准号:8550320
-
项目类别:
-
资助金额:$60.56万
-
财政年份:2013
-
负责人:SAMUEL M BEHAR
-
依托单位:
Regulation of CD8+ T cell immunity to tuberculosis (pending title)
-
批准号:8884534
-
项目类别:
-
资助金额:$64.78万
-
财政年份:2013
-
负责人:SAMUEL M BEHAR
-
依托单位:
Apoptosis and efferocytosis: regulators of immunity to tuberculosis
-
批准号:8993894
-
项目类别:
-
资助金额:$49.62万
-
财政年份:2013
-
负责人:SAMUEL M BEHAR
-
依托单位:
Apoptosis and efferocytosis: regulators of immunity to tuberculosis
-
批准号:8791297
-
项目类别:
-
资助金额:$49.62万
-
财政年份:2013
-
负责人:SAMUEL M BEHAR
-
依托单位:
Tim3 and Mycobacterium tuberculosis
-
批准号:8652944
-
项目类别:
-
资助金额:$52.91万
-
财政年份:2013
-
负责人:SAMUEL M BEHAR
-
依托单位:
Apoptosis and efferocytosis: regulators of immunity to tuberculosis
-
批准号:8605506
-
项目类别:
-
资助金额:$49.54万
-
财政年份:2013
-
负责人:SAMUEL M BEHAR
-
依托单位:
Tim3 and Mycobacterium tuberculosis
-
批准号:8629422
-
项目类别:
-
资助金额:$49.44万
-
财政年份:2013
-
负责人:SAMUEL M BEHAR
-
依托单位:
The effect of type I IFN and IL-12 signaling on T cell immunity to tuberculosis
-
批准号:8629409
-
项目类别:
-
资助金额:$20.81万
-
财政年份:2013
-
负责人:SAMUEL M BEHAR
-
依托单位:
Regulation of CD8+ T cell immunity to tuberculosis
-
批准号:10397020
-
项目类别:
-
资助金额:$70.46万
-
财政年份:2013
-
负责人:SAMUEL M BEHAR
-
依托单位:
Regulation of CD8+ T cell immunity to tuberculosis (pending title)
-
批准号:8711279
-
项目类别:
-
资助金额:$64.78万
-
财政年份:2013
-
负责人:SAMUEL M BEHAR
-
依托单位:
Regulation of CD8+ T cell immunity to tuberculosis
-
批准号:9918239
-
项目类别:
-
资助金额:$70.46万
-
财政年份:2013
-
负责人:SAMUEL M BEHAR
-
依托单位:
Apoptosis and efferocytosis: regulators of immunity to tuberculosis
-
批准号:8629352
-
项目类别:
-
资助金额:$33.82万
-
财政年份:2013
-
负责人:SAMUEL M BEHAR
-
依托单位:
Apoptosis and efferocytosis: regulators of immunity to tuberculosis
-
批准号:8416345
-
项目类别:
-
资助金额:$9.89万
-
财政年份:2012
-
负责人:SAMUEL M BEHAR
-
依托单位:
海外基金